EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015–2022). The beneficial effects of prenatal treatment on clinical outcomes of infected newborns

Borja Guarch-Ibáñez iD, Clara Carreras-Abad, Marie Antoinette Frick, Daniel Blázquez-Gamero, Fernando Baquero-Artigao, Isabel Fuentes, Spanish Research Network of Congenital Toxoplasmosis (REIV-TOXO) group, Pere Soler-Palacin

PLOS Neglected Tropical Diseases · 2024

DOI: 10.1371/journal.pntd.0012619 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Borja Guarch-Ibáñez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Catalonia, Spain. Hauptthemen laut MEDLINE: Toxoplasmosis, Congenital. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, BESCOS-MANAU FAMILY.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Some regions of Spain are withdrawing their pregnancy screening program for congenital toxoplasmosis (CT). The Spanish Research Network of Congenital Toxoplasmosis (REIV-TOXO) was created to describe the current status of CT in Spain. The aims of this study were to describe the epidemiological and clinical characteristics of CT and to evaluate the effect of prenatal treatment on clinical outcomes to inform decision-making policies.

Methods

Ambispective observational study including CT cases recorded in the REIV-TOXO database that includes 122 hospitals (2015–2022). Inclusion criteria were one or more of the following: positive PCR in maternal amniotic fluid; positive Toxoplasma gondii -specific IgM or IgA antibodies at birth; positive PCR in the placenta, newborn blood, urine or CSF; increase of specific IgG levels during infant follow-up; or specific IgG persistence beyond age 12 months.

Findings

Fifty-six newborns (54 pregnancies) were included. Prenatal screening allowed 92.8% of cases to be identified. The time of maternal infection was well documented in 90.7% of cases, with 61.1% occurring in the third trimester. A total of 66.6% (36/54) pregnant women received antiparasitic treatment: 24/36 spiramycin, 8/36 pyrimethamine, sulfadiazine, and folinic acid, and 4/36 both treatments sequentially. Most cases were asymptomatic at birth (62.5%, 35/56), and 84% (47/56) newborns completed one year of treatment. Median follow-up was 24 months (IQR = 3–72): 14.2% children exhibited new complications, mainly ocular. Newborns born to mothers treated prenatally had four-fold lower risk of CT clinical features at birth (p = 0.03) and six-fold lower risk of further complications during follow-up (p = 0.04) with no treatment-related differences during pregnancy.

Conclusions

While diagnosis based only on neonatal assessment misses a significant number of CT cases, prenatal screening allows treatment to be started during pregnancy, with better clinical outcomes at birth and during follow-up. REIV-TOXO provides valuable information about CT in Spain, highlighting the need for universal maternal screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toxoplasmosis, CongenitalHumansFemalePregnancyInfant, NewbornSpainAdultToxoplasmaMaleAntiprotozoal AgentsAntibodies, ProtozoanPrenatal DiagnosisPregnancy Complications, ParasiticCohort StudiesImmunoglobulin GTreatment OutcomePyrimethaminePrenatal Care

Substanzen

Antiprotozoal AgentsAntibodies, ProtozoanImmunoglobulin GPyrimethamine

Autor:innen und Institutionen

  • Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Catalonia, Spain.
  • Universitat de Girona (UDG), Girona, Catalonia, Spain.
  • Congenital Infections Working Group, Spanish Society of Pediatric Infectious Diseases (SEIP), Spain.
  • Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain.
  • Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Infantil Vall d'Hebron, Barcelona, Catalonia, Spain.
  • Vall d'Hebron Research Institute, Barcelona, Catalonia, Spain.

ORCID-Profile: Borja Guarch-Ibáñez

Förderung

  • Instituto de Salud Carlos III
  • BESCOS-MANAU FAMILY

Zitieren

APA

Guarch-Ibáñez, B., Carreras-Abad, C., Frick, M. A., Blázquez-Gamero, D., Baquero-Artigao, F., Fuentes, I., Spanish Research Network of Congenital Toxoplasmosis (REIV-TOXO) group, & Soler-Palacin, P. (2024). REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015–2022). The beneficial effects of prenatal treatment on clinical outcomes of infected newborns. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012619

Vancouver

Guarch-Ibáñez B, Carreras-Abad C, Frick MA, Blázquez-Gamero D, Baquero-Artigao F, Fuentes I, et al. REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015–2022). The beneficial effects of prenatal treatment on clinical outcomes of infected newborns. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012619

BibTeX
@article{GuarchIbez2024,
  author = {Guarch-Ibáñez, Borja and Carreras-Abad, Clara and Frick, Marie Antoinette and Blázquez-Gamero, Daniel and Baquero-Artigao, Fernando and Fuentes, Isabel and Spanish Research Network of Congenital Toxoplasmosis (REIV-TOXO) group, Spanish Research Network of Congenital Toxoplasmosis (REIV-TOXO) group and Soler-Palacin, Pere},
  title = {REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015–2022). The beneficial effects of prenatal treatment on clinical outcomes of infected newborns},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2024},
  doi = {10.1371/journal.pntd.0012619}
}
Kostenlos starten →